Relay Therapeutics Inc (RLAY) Implied Volatility Current

Tracking RLAY implied volatility helps you identify when options premiums on Relay Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Relay Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when RLAY IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Relay Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For RLAY, tracking metrics like RLAY IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on RLAY signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors.

It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where RLAY implied volatility sits today versus where it has been. Our scanner ranks Relay Therapeutics Inc implied volatility against its historical range, surfaces extremes in RLAY IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Relay Therapeutics Inc IV is rich or cheap — measure it, then act on it.